ABSTRACT
INTRODUCTION
Despite advances in obstetric, neonatal and cardiac care, congenital heart defects (CHDs) remain the leading cause of infant mortality secondary to birth defects 1 . The improvement in outcomes has led to a shift in focus from cardiac morbidity and mortality towards neurodevelopmental outcome 2 -6 . Historically, neurodevelopmental delay in children with CHDs was attributed to brain injury during their cardiac surgery 7 -10 . However, this assumption may not be true. Studies have reported a high prevalence of brain lesions on neuroimaging 11 -15 and a significant risk of neurodevelopmental delay 16 -18 before cardiac surgery and in those who did not undergo cardiac surgery.
We have reported previously that the incidence of brain lesions on conventional imaging before surgery was 34% in cases of transposition of the great arteries (TGA) and 49% in left-sided heart lesions 19 . Moreover, 40% of these newborns/infants exhibit impaired neurodevelopment 19 . These findings generated animated discussion among fetal medicine specialists and pediatric cardiologists, in particular in relation to TGA, for which the surgical outcome has been very successful. However, these findings are consistent with those of a landmark study investigating the long-term outcome of CHD, in which 33% of children with TGA at 16 years of age who had undergone the arterial-switch operation as infants had brain abnormalities on magnetic resonance imaging (MRI), and 65% received remedial academic or behavioral treatment 20 . Key questions are whether these brain abnormalities are already present before birth; if so, what is the underlying mechanism and could prenatal intervention alter the outcome? One possible explanation for the high incidence of brain abnormalities and neurodevelopmental impairment is that these neonates may have suffered the 'injuries' postnatally, for example, when the arterial duct closed 19 . Our previous meta-analysis included newborns and infants, but not fetuses, in order to avoid clinical heterogeneity. Therefore, we could not investigate the prevalence of these abnormalities before birth in fetuses with CHD 19 . Fewer studies have investigated prenatal brain development in fetuses with CHD than have investigated brain development postnatally in babies 21 -24 . The prevalence of brain abnormalities demonstrated on fetal MRI was reported to be as high as 39% 22 . The primary aim of this study was to perform a systematic review to quantify the prevalence of brain abnormalities in fetuses with apparently isolated CHD.
METHODS

Protocol, eligibility criteria, information sources and search
This review was performed according to a protocol designed a priori and recommended for systematic reviews and meta-analyses 25 -27 . MEDLINE (1966 to July 2015), EMBASE (1974 to July 2015) and The Cochrane Library (from inception), including The Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and The Cochrane Central Register of Controlled Trials (CENTRAL), were searched electronically on 18 November 2014, and the search was updated on 6 August 2015, utilizing combinations of the relevant MeSH terms, keywords and word variants for 'congenital heart', 'cardiac', 'neurologic', 'MRI', 'ultrasound', 'neuroimaging', 'brain', 'outcome' (Table  S1) . No language restrictions were imposed on the search or selection criteria. Reference lists of relevant articles and reviews were hand-searched for additional reports. The STROBE guidelines were followed 27 . The study was registered with the PROSPERO database (Registration number CRD42015025546, http://www.crd.york.ac.uk/ PROSPERO).
Study selection, data collection and data items
Studies were assessed according to the following criteria: population, outcome, study design, gestational age at testing, imaging modality and type of CHD. Studies reporting brain abnormalities or changes on neuroimaging in fetuses with CHD were included. Cases were excluded if they had undergone prenatal cardiac surgical intervention, if they had other structural abnormalities (apart from of the heart or brain) or if they had known genetic/ chromosomal anomalies.
All abstracts were reviewed independently by two authors (S.B., A.K.). Agreement regarding potential relevance was reached by consensus, and full-text copies of those papers deemed to be relevant were obtained. The same two reviewers independently extracted data regarding study characteristics and outcomes. Inconsistencies were discussed by the reviewers and consensus was reached. For those articles in which information was not reported but the methodology was such that this information would have been recorded initially, the authors were contacted (but no response was received). If more than one study had been published for the same cohort with identical endpoints, the report containing the most comprehensive information on the population was included to avoid overlapping populations.
The outcomes observed in this systematic review were:
(1) Structural brain abnormalities. These included anatomical brain abnormalities, such as periventricular leukomalacia and malformations of cortical development. The detection method was fetal brain MRI, as some brain abnormalities can be detected by prenatal MRI but not by ultrasound. The ascertainment method when performed was postnatal brain imaging or postmortem examination. (2) Changes in brain volume. These included significantly smaller brain volume when compared with controls (fetuses without CHD) or the gestational age-expected normal range, or a progressive decline in brain volume when assessed longitudinally, indicating reduced growth rate. The detection methods included fetal brain MRI, three-dimensional (3D) volumetric MRI, 3D ultrasound and phase-contrast MRI. The ascertainment method when performed was postnatal brain imaging, but it was rarely reported in the studies. (3) Changes in brain metabolism or maturation. These included changes in the n-acetylaspartate (NAA)/ choline, inositol/choline or choline/creatinine ratio, oxygen saturation of the brain's blood supply or cerebral oxygen consumption. The detection methods included magnetic resonance spectroscopy and phase-contrast magnetic resonance. The ascertainment method when performed was postnatal brain imaging, but it was rarely reported in the studies. (4) Changes in brain blood flow. These included changes in the middle cerebral artery (MCA) pulsatility index or resistance index or their Z-scores, cerebroplacental ratio (CPR), ratio of umbilical artery (UA) PI to Prospective and retrospective cohorts, case-control studies and case series with more than three fetuses with CHD were included. Case reports, conference abstracts and editorials were excluded. Studies reporting changes in head size without associated brain changes were excluded to avoid overinterpreting these findings as brain abnormalities. Studies in which data on robust outcomes could be extracted were included.
Risk of bias, summary measures and synthesis of the results
Quality assessment of the included studies was performed using the Strengthening the Reporting of Observational Studies in Epidemiology statement criteria 27 . We used random-effects meta-analyses of proportions to combine data on the prevalence of structural brain abnormalities in fetuses with CHD 28, 29 . The small number of studies/cases did not permit meaningful stratified meta-analyses according to the type of CHD, except for tetralogy of Fallot (TOF). Between-study heterogeneity was assessed using the I 2 statistic 30 . Publication bias was explored using funnel plots and was assessed statistically using the Egger test (which uses the actual values of the effect sizes and their precision, rather than ranks) 31 . Assessment of potential publication bias was problematic because of the low number of individual studies, which strongly limits the reliability of formal tests. Funnel plots displaying the outcome rate from individual studies vs their precision (1/standard error) were carried out with an exploratory aim. Tests for funnel-plot asymmetry were not used when the total number of publications included for each outcome was less than 10. In this case, the power of the tests is too low to distinguish chance from real asymmetry 32 .
Statistical analysis was performed using Stats Direct Version 2.7.8 statistical software (Stats Direct Ltd, Altrincham, Cheshire, UK).
RESULTS
The search yielded 1943 citations, of which 1883 were excluded by review of the title or abstract, as they did not meet the selection criteria or contain original data, were not relevant or contained postnatal data only (Figure 1 ). Full manuscripts were retrieved for the remaining 60 studies and a total of 20 (n = 1175 cases of CHD) were included in the review. Three studies reported data on structural brain abnormalities, while data on altered brain volume, metabolism and blood flow were reported in seven, three and 14 studies, respectively (Figure 1) . The three studies (221 cases) reporting data on structural brain abnormalities were suitable for inclusion in a meta-analysis. Table 1 shows the findings of the included studies that reported structural brain abnormalities. Fetal brain MRI was performed in the second half of pregnancy, between 18 and 39 weeks' gestation. The most commonly reported abnormality was ventriculomegaly (8.6% of fetuses with CHD). Other abnormalities included malformation or delay of cortical development (4.5%), vermian hypoplasia (1.4%), agenesis of the corpus callosum (ACC) (0.9%), holoprosencephaly (0.5%), cerebellar hypoplasia (0.5%), ventricular bleeding (0.5%), enlarged subarachnoid space (1.9%) and germinolytic or periventricular cysts (5.1%) 22 -24 . The pooled prevalence of structural brain abnormalities was 59/221 (28% (95% CI, 18-40%), I 2 = 63.8%; Figure 2 ). As the number of cases in most studies was too small to report their findings according to the type of CHD, some studies categorized CHDs according to their hemodynamic changes. One study classified these brain abnormalities into malformations (such as ACC, malformation of cortical development and DandyWalker malformation), acquired lesions (such as periventricular leukomalacia, stroke and white-matter injury) and widening of the ventricles and/or outer cerebrospinal fluid spaces 22 . Subgroup analysis was possible in cases with TOF, for which data from two studies could be pooled 23, 24 . The prevalence of structural brain abnormalities in fetuses with TOF was 10/41 (25% (95% CI, 14-39%); Figure 3 ). Table 2 illustrates the findings of the included studies that reported on changes in brain volume. Neuroimaging was performed using either fetal brain MRI or 3D/four-dimensional ultrasound, and was performed in the second half of pregnancy in all studies except for one, in which ultrasound brain assessment was performed as early as 14 weeks' gestation 33 . Of note is that this was the only study that did not show a different growth pattern in fetuses with CHD when compared with the control group 33 . Pooling of the data reported in these studies was not possible owing to the clinical heterogeneity and lack of a consistent method of reporting the data quantitatively. All of these studies had a case-control design and most included mixed types of CHD, except for two studies reporting on hypoplastic left heart syndrome (HLHS) and TOF 23, 34 . Studies reported a significant delay in cortical gyrification and shallower parieto-occipital, cingulate and calcarine fissures, when compared with controls 34, 35 . Table 3 shows the findings of the studies that reported on changes in brain metabolism. Functional brain MRI was performed in the third trimester 21, 35, 36 . Similar to the brain volume changes, pooling of the data on altered brain metabolism was not possible owing to the clinical heterogeneity. However, all three studies were consistent in reporting significantly altered brain metabolism and oxygen saturation in fetuses with CHD. The reported abnormalities included a change in the NAA/choline, inositol/choline and choline/creatinine ratios 21, 35, 36 .
Structural brain abnormalities in fetuses with CHD
Changes in brain volume in fetuses with CHD
Changes in brain metabolism or maturation in fetuses with CHD
Changes in brain blood flow in fetuses with CHD Table 4 shows the findings of the studies that reported on changes in fetal brain blood circulation. Circulatory changes were assessed using Doppler ultrasound performed in the second and third trimesters 35,37 -48 , except for one study in which functional MRI was used 36 . The cerebral vessel most commonly studied was the MCA, often combined with UA Doppler as the CPR. As both the MCA and UA pulsatility indices change with gestational age, some studies adjusted for this potential confounding factor using either Z-scores or centiles 35,37 -48 . In view of the clinical heterogeneity in the gestational age at assessment, vessel examined, variables reported and types of CHD, pooling of the data was not attempted. However, CPR was significantly lower in fetuses with CHD when compared with that of controls in more than half (8/14) of the studies 35 
Quality assessment of the included studies
The quality of the studies is summarized in Figure 4 . Among the studies included in this review, the title, abstract, background, objectives, study design, assessment methods and the interpretation of the studies were described appropriately in 100%. On the other hand, explanation of study size (sample size calculation) was reported in none, and flow diagrams to describe the study population were rarely used. However, statistical methods were described in 90% of these studies. The study setting, recruitment period, eligibility, matching criteria, data variables and summary of the key findings were adequately described in more than 70%. Efforts to address bias and acknowledge the limitations of the study were reported in approximately 50% of studies ( Figure 4 ).
DISCUSSION
Summary of findings
This meta-analysis suggests that CHD is associated with an unexpectedly high prevalence of prenatal structural brain abnormalities, reduced brain volume, delay in brain maturation and altered brain circulation. These changes are detected on third-trimester neuroimaging, but some may be detected as early as the second trimester. Data for gestational age at assessment (GA) are given as mean (range), mean ± SD (range) or mean ± SD (median). Only first author is given for each study. *Group 1: pulmonary artery is smaller than aorta (n = 18); Group 2: aorta is smaller than pulmonary artery (n = 10); Group 3: both aorta and pulmonary artery are normal in size (n 
Interpretation of the findings
Are the brain abnormalities present before or after birth?
The overall prevalence of structural brain abnormalities is increased, but to a slightly lower degree than we reported previously, in newborns/infants with CHD before cardiac surgery or in those who did not have cardiac surgery 19 . The brain abnormalities reported here during fetal life are similar to those reported after birth, in particular ventriculomegaly, ACC, ventricular bleeding, enlarged subarachnoid space and brain cysts 19 . Both meta-analyses included observational studies, with their inherent risks of bias and possible over-or under-reporting of brain abnormalities in cases with CHD. A main limitation of the previous meta-analysis, which we have addressed in the current review, was an inability to clarify whether the reported brain abnormalities detected on neuroimaging had occurred before or after birth. The fact that the prevalence of brain abnormalities reported in fetuses was slightly lower than that reported in newborns with CHD before or without surgery suggests that peripartum events are unlikely to be the main contributor. The findings of the current systematic review, which was limited to the findings of antenatal neuroimaging, are consistent with those of pathological studies 49, 50 . Almost half of the babies with HLHS had associated congenital brain abnormalities in pathological studies 49, 50 . We did not include pathological studies in this review in order to avoid clinical heterogeneity.
What is the explanation for this association between brain abnormalities and CHD?
Conventionally, G-banded karyotyping is used to exclude aneuploidy. However, compared with routine karyotyping, up to 6% of additional clinically relevant deletions or duplications can be diagnosed in fetuses with a structural anomaly using microarray analysis 51 . In cases with CHD, the incremental yield is as high as 16% 52 . This suggests that undiagnosed chromosomal aberrations could explain the reported association with structural brain abnormalities. Furthermore, in some of the studies the excluded chromosomal abnormalities were limited to 22q11 microdeletion and trisomies 13, 21 and 18. In the study by Mlczoch et al. 22 , chromosomal analysis was not performed in 31/53 cases. Similarly, in 37% of cases reported by Schellen et al. 23 there was no genetic work-up. However, a recent study reported no difference in brain size and/or oxygenation between syndromic and non-syndromic fetuses with CHD 36 , which makes a genetic origin of the observed brain changes unlikely. Data for gestational age at assessment (GA) are given as median (range), range, mean ± SD or mean ± SD (median). Only first author is given for each study. *This study includes a subpopulation from study by Limperopoulos et al.
21
. †Authors described study as cohort, but includes controls (case-control). ‡Three fetuses had chromosomal abnormalities and three had associated abnormalities (excluded from this review). 3D, three-dimensional; 4D, four-dimensional; ctrls, controls; eCSFV, external cerebrospinal fluid volume; GMV, gray-matter volume; HLHS, hypoplastic left heart syndrome; ICV, intracranial cavity volume; MRI, magnetic resonance imaging; PC, phase-contrast; prosp, prospective; retro, retrospective; SBV, subcortical brain volume; TBV, total brain volume; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; US, ultrasound; vol, volumetric; VV, ventricular volume. 
MRS
Increased inositol/choline ratio in frontal lobe and basal ganglia, decreased levels of NAA/choline and choline/creatinine ratios in both areas in CHD fetuses vs ctrls. Peak in lactate level identified in three CHD cases (one with critical aortic stenosis and hypoplastic left heart syndrome, one transposition of great vessels and one tricuspid atresia with hypoplastic right ventricle)
Data for gestational age at assessment (GA) are given as median (range), mean ± SD or range. Only first author is given for each study. *Authors described study as a cohort study, but includes controls (case-control). †Three fetuses had chromosomal abnormalities and three had associated abnormalities (excluded from this review). ctrls, controls; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; PC, phase-contrast; prosp, prospective; retro, retrospective.
An alternative explanation for this association could be altered cerebral circulation in utero in fetuses with CHD 35,37 -47 . This hypothesis is supported by the finding of a higher prevalence of brain lesions among babies with left-sided heart lesions in postnatal studies, compared with the prevalence in cases of TGA 19, 53, 54 .
Does the association between brain abnormalities and CHD vary according to the type of CHD?
The risk of brain abnormalities detected in neonates/ infants before cardiac surgery seems to be greatest in left-sided heart lesions, e.g. HLHS 19 . However, the brain abnormalities and impaired brain growth reported in fetuses with TOF from as early as the second trimester question the assumption that fetuses with right ventricular outflow tract obstruction are less affected by altered cerebral perfusion than are fetuses with left-sided heart lesions 23 . In a recent study, the type of CHD was not significantly associated with the risk of abnormal brain neurodevelopment 35 , and prenatal brain changes and childhood developmental delay have also been demonstrated in CHD types that are associated with normal brain perfusion during fetal life 41, 55 . Therefore, simply relying on the type of CHD as a predictor of the risk of impaired brain development is not likely to be clinically useful, and larger prospective studies are required to investigate this more fully.
How early can brain abnormalities be detected in fetuses with CHD?
Smaller head size is commonly described in fetuses with CHD 35, 47 . As a small head per se does not necessarily equate to brain abnormality or neurodevelopmental delay, we have excluded data on small head size unless it was associated with brain abnormalities. These brain changes can be detected from as early as 25 weeks' gestation, and as early as 20 weeks in fetuses with TOF 23, 24 . This altered brain development might already be present in affected fetuses from as early as 20 weeks, and degenerative changes in the developing cortex become increasingly apparent during the late third trimester 21, 34 .
Strengths and limitations of the systematic review
The quality of the data available for meta-analysis limits the current study findings. Small numbers and selection bias of retrospective reviews were the general drawbacks. With specific reference to the type of CHD, the lack of extractable data on clinical subgroups of CHD and the clinical heterogeneity among the studies are likely to have resulted in under-or over-reporting of these adverse outcomes.
Clinical and research implications of the review findings
There is growing evidence indicating a prenatal effect of CHDs on brain development, implying that postnatal Table 4 Summary of studies included in systematic review reporting on changes in brain blood flow in fetuses with congenital heart defects (CHD) Study Figure 4 Bar chart showing quality criteria of articles included in systematic review, assessed using checklist of Strengthening the Reporting of Observational Studies in Epidemiology 27 . , yes; , no.
neuroprotective interventions are likely to be of limited value. An important question is whether the delay in brain growth, development and maturation results in significant neurodevelopmental delay and, if so, whether it might be possible to identify those fetuses at increased risk and ultimately improve postnatal outcome. First, Bayley Scales of Infant and Toddler Development (BSID-III) average scores were found to be significantly correlated to total brain volume, cingulated fissure depth and inositol/choline and NAA/ choline ratios 35 . Second, cerebrovascular resistance is associated with higher neurodevelopmental scores in fetuses with single-ventricle anomalies 56 . Third, brain dysmaturation is associated with increased susceptibility to white-matter injury. Fourth, these brain changes can potentially be detected as early as 25 weeks' gestation, but more importantly, hemodynamic brain changes recorded as early as 20 weeks can identify fetuses that will manifest delayed brain growth and maturation, and ultimately those that will suffer from neurodevelopmental impairment 35 . A more exciting finding, recently reported by Sun et al. 36 , is a proposed direct link between reduced cerebral oxygenation and impaired brain growth in fetuses with CHD, which raises the possibility of an improvement of in-utero brain development using maternal oxygen therapy.
Based on the findings of this meta-analysis, we would recommend a prospective longitudinal study in which cases with CHD have fetal brain MRI in the third trimester and, after birth, close periodic developmental surveillance follow-up. Despite the fact that the American Heart Association recommends periodic developmental surveillance, screening, evaluation and re-evaluation throughout childhood in children with CHD 57 , it is not currently routine to screen for brain abnormalities or neurodevelopmental delay in newborns with CHD. The evidence from this meta-analysis and other studies calls for a policy that recommends early assessment of these cases, starting from fetal life. Finally, identification of significant brain abnormalities during fetal life might also influence the parents' decision as to whether to continue the pregnancy following antenatal counseling. In response to these findings the International Society of Ultrasound in Obstetrics and Gynecology is developing a consensus on how these pregnancies should be counseled prenatally, including how to convey these findings and the limitations of the published literature.
